Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1513450 | 0.85 | KDM4E (0.56) | RBP4MEN1KMT2AALDH1A1POLB | |
| SCHEMBL28742767 | 0.84 | RBP4 (0.45) | RBP4MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL28942169 | 0.81 | RBP4 (0.50) | RBP4MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL19926965 | 0.80 | RBP4 (0.52) | RBP4MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2636989 | 0.80 | RBP4 (0.52) | RBP4MEN1KMT2ACYP2C19BRD4 | |
| SCHEMBL21885656 | 0.80 | BACE1 (0.52) | RBP4MEN1KMT2AALDH1A1POLB | |
| SCHEMBL2636181 | 0.80 | RBP4 (0.49) | RBP4MEN1KMT2ACYP2C19SCD5 | |
| SCHEMBL27900121 | 0.80 | TRPV1 (0.55) | RBP4MEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL23123039 | 0.80 | RBP4 (0.43) | RBP4MEN1KMT2AALDH1A1POLB | |
| SCHEMBL2637112 | 0.80 | RBP4 (0.81) | RBP4CYP2D6CYP2C19SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214460-A | Chemical compounds | SYNGENTA PARTICIPATIONS AG | 2013-07-24 | — | — | CN | claimed |
| CN-1976584-A | Compound (I) | SYNGENTA PARTICIPATIONS AG (CH) | 2007-06-06 | — | — | CN | claimed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11731958-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3755703-B1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORP (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210094934-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| EP-3755703-A1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | Incyte Corporation (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10800761-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2019164846-A1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| CN-1322196-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N N (SE) | 2001-11-14 | — | — | CN | disclosed |
| CN-1309638-A | N-substituted naphthamides as neurokinin receptor antagonists | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800761-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | RBP4 4612/4885MEN1 2274/4885KMT2A 1609/4885 |
| US-11731958-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | RBP4 4612/4885MEN1 2274/4885KMT2A 1609/4885 |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | PCK1, PHKG2, PHKG1 | RBP4 4612/4885MEN1 2274/4885KMT2A 1609/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | RBP4 1528/4885MEN1 1124/4885KMT2A 1616/4885 |
| US-20210094934-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | PCK1, PHKG2, PHKG1 | RBP4 4612/4885MEN1 2274/4885KMT2A 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.